Catherine D. Strader, Ph.D., has been a member of Acorda’s Board of Directors since February 2017. Dr. Strader is a founding partner at Synergy Partners R&D Solutions, a consultancy network which advises biotechnology companies on research and development strategies. Prior to founding Synergy Partners, Dr. Strader worked at Merck Research Laboratories in roles of increasing responsibility, most recently as Vice President and Discovery Site Head, where she led an external research initiative to build Merck’s early-stage pipeline using external sources of innovation. Dr. Strader held leadership positions at Schering-Plough before the company was acquired by Merck, including Executive Vice President of Discovery Research and Chief Scientific Officer. In that role, she had both strategic and operational responsibility for the company’s global small molecule and biologics discovery research and early development portfolio. She has guided more than 50 compounds through drug discovery and development during her career. Dr. Strader received a B.S. in Chemistry from the University of Virginia and a Ph.D. in Chemistry from the California Institute of Technology, followed by a Howard Hughes postdoctoral fellowship at Duke University. She is the author of more than 150 scientific publications. Catherine D. Strader, Ph.D., has been a member of Acorda’s Board of Directors since February 2017. Dr. Strader is a founding partner at Synergy Partners R&D Solutions, a consultancy network which advises biotechnology companies on research and development strategies. Prior to founding Synergy Partners, Dr. Strader worked at Merck Research Laboratories in roles of increasing responsibility, most recently as Vice President and Discovery Site Head, where she led an external research initiative to build Merck’s early-stage pipeline using external sources of innovation. Dr. Strader held leadership positions at Schering-Plough before the company was acquired by Merck, including Executive Vice President of Discovery Research and Chief Scientific Officer. In that role, she had both strategic and operational responsibility for the company’s global small molecule and biologics discovery research and early development portfolio. She has guided more than 50 compounds through drug discovery and development during her career. Dr. Strader received a B.S. in Chemistry from the University of Virginia and a Ph.D. in Chemistry from the California Institute of Technology, followed by a Howard Hughes postdoctoral fellowship at Duke University. She is the author of more than 150 scientific publications.

Management